Data Article

Dataset of total, oligomeric alpha-synuclein and hemoglobin levels in plasma in Parkinson’s disease

A. Emelyanova, P. Andoskin, S. Pchelina

A. Petersburg Nuclear Physics Institute, St. Petersburg, Russia
B. Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia
C. St. Petersburg Academic University - Nanotechnology Research and Education Centre, RAS, St. Petersburg, Russia
D. Institute of Experimental Medicine, St. Petersburg, Russia

Article history:
Received 22 October 2016
Received in revised form 18 November 2016
Accepted 23 November 2016
Available online 28 November 2016

Abstract

This data article presents a dataset of total, oligomeric alpha-synuclein and hemoglobin levels in plasma of drug-naïve PD patients and controls. This is the first attempt to assess the effect of hemolysis rate on oligomeric alpha-synuclein levels in peripheral plasma. The data are associated with the research article “Oligomeric alpha-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson’s disease” (Pchelina et al., 2016) [1].

© 2016 Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Specifications Table

| Subject area          | Medicine                                  |
|-----------------------|-------------------------------------------|
| More specific subject area | Neurology, Neurodegenerative diseases     |
| Type of data          | Table, Graph                              |
How data was acquired
Enzyme-linked immunosorbent assay (ELISA), Microplate Spectrophotometer, SPSS 12.0

Data format
Analysed

Experimental factors
Blood plasma samples were collected using centrifugation

Experimental features
The relationship between total, oligomeric alpha-synuclein and hemoglobin levels in plasma in Parkinson’s disease was determined.

Data source location
St.Petersburg, Russian Federation

Data accessibility
Data is within this article

Value of the data

- These data provide the correlation between oligomeric alpha-synuclein and hemoglobin plasma levels in drug-naive PD patients and controls.
- The data are of value for further experiments on the assessing of alpha-synuclein levels in peripheral blood and cerebrospinal fluid (CSF) samples.
- The data have significance due to the fact that hemolysis has effect on total but not oligomeric alpha-synuclein levels in peripheral blood plasma.

1. Data

Significant positive correlation of total alpha-synuclein with hemoglobin levels was observed in combined group of iPD patients and controls ($r=0.714; p<0.0001$) and separately (for iPD patients – $r=0.656; p=0.004$; for controls – $r=0.746; p<0.0001$) (Fig. 1). However, the correlation between oligomeric alpha-synuclein and hemoglobin levels in the above mentioned groups was absent (for combined group – $r=0.198; p=0.254$; for iPD – $r=0.234; p=0.366$; for controls – $r=0.049; p=0.848$). We did not find any significant difference in total, oligomeric alpha-synuclein levels and oligomeric/total alpha-synuclein ratio between iPD patients and controls (Table 1) [1].

Fig. 1. Correlation between alpha-synuclein species and hemoglobin plasma levels in combined group of PD patients and controls. (A) Positive correlation between total alpha-synuclein and hemoglobin levels ($r=0.714; p<0.0001$). (B) Correlation between oligomeric alpha-synuclein and hemoglobin levels ($r=0.198; p=0.254$).
2. Experimental design, materials and methods

2.1. Sample preparation

Blood plasma samples were collected from 17 drug-naïve patients with iPD (mean age 62.44 ± 9.67, 6 males) and age/sex-matched 18 controls (mean age 63.83 ± 10.86, 10 males). PD patients were diagnosed with PD at Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia. Subjects without neurological disorders were included in the control group. The study was approved by the local ethics committee. All the participating subjects provided informed consent. Samples were collected using centrifugation at 3000 rpm at 4 °C for 20 min. All samples were aliquoted and maintained at −70 °C.

2.2. ELISA assays to measure total, oligomeric alpha-synuclein and hemoglobin levels

Total alpha-synuclein, oligomeric alpha-synuclein and hemoglobin levels were estimated by means of enzyme-linked immunosorbent assay (ELISA) (Human alpha-synuclein ELISA kit (Invitrogen, USA), Human Synuclein OLIGO kit (ajRoboscreen, Germany) and Hemoglobin (Human) ELISA kit (Abnova, USA), accordingly), as described previously [2–4]. Levels of oligomeric alpha-synuclein were estimated by means of ELISA with 5G4 antibodies designated for detection of alpha-synuclein oligomers in human fluid samples [5]. Undiluted plasma samples were examined in case of alpha-synuclein measurements. For hemoglobin level estimation plasma samples were diluted according the manufacturer’s recommendations. In all ELISA assays each sample was measured in triplicate.

2.3. Statistical analysis

To assess differences between groups, the Mann–Whitney test was used, and the correlations were evaluated by exponential regression analysis. The correlations were evaluated using the Spearman correlation coefficient. Sex variables were analyzed by Chi-square and Fisher's exact tests. Experimental data are given as median (min–max). The level of significance was set at $p < 0.05$. Statistical analysis was carried out using SPSS 12.0.

Acknowledgment

We wish to thank the Russian Foundation for Basic Research (research Project no. 16-54-76009) and the ERA.Net RUS Plus Group of Funding Parties (ID230) for financial support.

Transparency document. Supplementary material

Transparency data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.dib.2016.11.089.
References

[1] S. Pchelina, A. Emelyanov, G. Baydakova, P. Andoskin, M. Nikolaev, K. Senkevich, I. Milyukhina, A. Yakimovskii, A. Timofeeva, E. Fedotova, N. Abramycheva, T. Usenko, D. Kulabukhova, A. Kopytova, E. Nuzhnyi, S. Illarioshkin, E. Zakharova, Oligomeric alpha-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson’s disease, Neurosci. Lett. (2016) (pii: S0304-3904(16)(30792-3).

[2] R. Duran, F.J. Barrero, B. Morales, J.D. Luna, M. Ramirez, F. Vives, Plasma alpha-synuclein in patients with Parkinson’s disease with and without treatment, Mov. Disord. 25 (2010) 489–493.

[3] M. Shi, C.P. Zabetian, A.M. Hancock, C. Ginghina, Z. Hong, D. Yearout, K.A. Chung, J.F. Quinn, E.R. Peskind, D. Galasko, J. Jankovic, J.B. Leverenz, J. Zhang, Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson’s disease, Neurosci. Lett. 480 (2010) 78–82.

[4] S.N. Pchelina, E.P. Nuzhnyi, A.K. Emelyanov, T.M. Boukina, T.S. Usenko, M.A. Nikolaev, G.N. Salogub, A.F. Yakimovskii, E.Y. Zakharova, Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases, Neurosci. Lett. 583 (2014) 188–193.

[5] G.G. Kovacs, U. Wagner, B. Dumont, M. Pikkarainen, A.A. Osman, N. Streichenberger, I. Leisser, J. Verchère, T. Baron, I. Alafuzoff, H. Budka, A. Perret-Liaudet, I. Lachmann, An antibody with high reactivity for disease-associated -synuclein reveals extensive brain pathology, Acta Neuropathol. 124 (2012) 37–50.